b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29111983</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>07</Month>\n            <Day>17</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>25</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1537-4513</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>41</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>01</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of immunotherapy (Hagerstown, Md. : 1997)</Title>\n                <ISOAbbreviation>J. Immunother.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>42-44</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1097/CJI.0000000000000191</ELocationID>\n            <Abstract>\n                <AbstractText>In the past decade, the resurgence of immunotherapy has changed the landscape of cancer therapy. Checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1 on lymphocytes, and programmed death ligand-1 on tumors cells are currently utilized in the management of several cancers. These agents are double-edged sword with the positive effect being robust antitumor response but on the other side they can throttle up the normal immunologic homeostasis in a negative way, leading to adverse autoimmune toxicities. These adverse toxicities are frequent if patients have active autoimmune disorders. Here, we report a rare case of quiescent bullous pemphigoid which flared after initiation of pembrolizumab, a programmed death ligand-1 inhibitor.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Garje</LastName>\n                    <ForeName>Rohan</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Departments of Hematology and Oncology.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chau</LastName>\n                    <ForeName>Justin J</ForeName>\n                    <Initials>JJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Internal Medicine.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chung</LastName>\n                    <ForeName>Jina</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Dermatology, University of Iowa Hospitals and Clinics, Iowa City, IA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wanat</LastName>\n                    <ForeName>Karolyn</ForeName>\n                    <Initials>K</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Dermatology, University of Iowa Hospitals and Clinics, Iowa City, IA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zakharia</LastName>\n                    <ForeName>Yousef</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Departments of Hematology and Oncology.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>P30 CA086862</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D002363">Case Reports</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Immunother</MedlineTA>\n            <NlmUniqueID>9706083</NlmUniqueID>\n            <ISSNLinking>1524-9557</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>DPT0O3T46P</RegistryNumber>\n                <NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>VB0R961HZT</RegistryNumber>\n                <NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005076" MajorTopicYN="N">Exanthema</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010392" MajorTopicYN="N">Pemphigus</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>\n                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012872" MajorTopicYN="N">Skin Diseases, Vesiculobullous</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001743" MajorTopicYN="N">Urinary Bladder</DescriptorName>\n                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014571" MajorTopicYN="N">Urologic Neoplasms</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D028761" MajorTopicYN="N">Withholding Treatment</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>7</Month>\n                <Day>18</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>11</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29111983</ArticleId>\n            <ArticleId IdType="doi">10.1097/CJI.0000000000000191</ArticleId>\n            <ArticleId IdType="pmc">PMC6339565</ArticleId>\n            <ArticleId IdType="mid">NIHMS1005068</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Dermatol Clin. 2011 Oct;29(4):555-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21924997</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Autoimmun Rev. 2014 Apr-May;13(4-5):477-81</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24424192</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2015 Feb 15;21(4):712-20</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25524312</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Melanoma Res. 2015 Jun;25(3):265-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">25831416</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Oncol. 2015 Dec;26(12):2375-91</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26371282</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Immunol Res. 2016 May;4(5):383-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26928461</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2016 Aug 15;22(16):4023-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26957557</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Eur J Cancer. 2016 Jun;60:12-25</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27043866</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Melanoma Res. 2016 Aug;26(4):421-4</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27135655</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Opin Oncol. 2016 Jul;28(4):254-63</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27136138</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>JAMA Oncol. 2016 Oct 1;2(10):1346-1353</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27367787</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Melanoma Res. 2016 Oct;26(5):540-3</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27482939</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Treat Options Oncol. 2016 Nov;17(11):57</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27645330</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Oncol. 2017 Feb 1;28(2):368-376</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27687304</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br Med J. 1978 Oct 28;2(6146):1190-1</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">363229</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'